145.26
price down icon1.14%   -1.67
after-market アフターアワーズ: 145.26
loading
前日終値:
$146.93
開ける:
$146.27
24時間の取引高:
678.59K
Relative Volume:
0.69
時価総額:
$14.48B
収益:
$2.41B
当期純損益:
$305.80M
株価収益率:
49.24
EPS:
2.95
ネットキャッシュフロー:
$492.20M
1週間 パフォーマンス:
+0.18%
1か月 パフォーマンス:
-4.17%
6か月 パフォーマンス:
+14.64%
1年 パフォーマンス:
+4.48%
1日の値動き範囲:
Value
$144.65
$146.78
1週間の範囲:
Value
$144.65
$148.56
52週間の値動き範囲:
Value
$84.23
$160.18

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1131)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
1,800
Name
Twitter
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

NBIX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
145.26 14.65B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
126.23 55.30B 9.40B 2.65B 2.24B 5.935
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.65 49.22B 29.63B 260.53M 5.51B 0.0788
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.13 44.97B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
31.89 36.41B 16.88B 666.71M 251.19M 0.6132
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
507.16 22.16B 3.08B 1.24B 1.07B 25.61

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-21 開始されました Citigroup Buy
2025-07-21 開始されました Truist Buy
2025-07-10 開始されました Goldman Buy
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
07:32 AM

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Rice Hall James & Associates LLC - MarketBeat

07:32 AM
pulisher
Dec 26, 2025

Neurocrine Biosciences director sells shares worth $269,167 - MSN

Dec 26, 2025
pulisher
Dec 25, 2025

Swedbank AB Has $76.83 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 25, 2025
pulisher
Dec 24, 2025

Neurocrine Biosciences (NBIX) Stock News: Brighton Jones Raises Stake to $1.43M - Eudaimonia and Co

Dec 24, 2025
pulisher
Dec 24, 2025

Brighton Jones LLC Has $1.43 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 24, 2025
pulisher
Dec 24, 2025

Neurocrine Biosciences Earnings Notes - Trefis

Dec 24, 2025
pulisher
Dec 23, 2025

AbbVie, Neurocrine End One Orilissa Patent Case Against Hetero - Bloomberg Law News

Dec 23, 2025
pulisher
Dec 23, 2025

Voya Investment Management LLC Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 23, 2025
pulisher
Dec 23, 2025

What's Going On With Neurocrine Biosciences Stock Tuesday?Neurocrine Biosciences (NASDAQ:NBIX) - Benzinga

Dec 23, 2025
pulisher
Dec 23, 2025

Neurocrine’s valbenazine misses Phase III goals in DCP - The Pharma Letter

Dec 23, 2025
pulisher
Dec 23, 2025

Neurocrine Biosciences (NBIX): Assessing Valuation After New Phase 2 Bipolar I Mania Trial Launch - Sahm

Dec 23, 2025
pulisher
Dec 22, 2025

Neurocrine : Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal - Nasdaq

Dec 22, 2025
pulisher
Dec 22, 2025

Neurocrine's Ingrezza fails in phase 3 trial for dyskinetic cerebral palsy (NBIX:NASDAQ) - Seeking Alpha

Dec 22, 2025
pulisher
Dec 22, 2025

Neurocrine's movement disorder treatment fails late-stage trial - marketscreener.com

Dec 22, 2025
pulisher
Dec 22, 2025

Neurocrine's Phase 3 Trial of Valbenazine in Dyskinetic Cerebral Palsy Fails to Meet Primary, Key Secondary Endpoints - marketscreener.com

Dec 22, 2025
pulisher
Dec 22, 2025

Neurocrine’s phase 3 trial for cerebral palsy drug fails to meet endpoints - Investing.com

Dec 22, 2025
pulisher
Dec 22, 2025

Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy - PR Newswire

Dec 22, 2025
pulisher
Dec 22, 2025

Assenagon Asset Management S.A. Sells 13,280 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 22, 2025
pulisher
Dec 21, 2025

Neurocrine’s Growth Story Runs Through INGREZZA And The Pipeline - Finimize

Dec 21, 2025
pulisher
Dec 21, 2025

HC Wainwright & Co. maintains Neurocrine Biosciences (NBIX) buy recommendation - MSN

Dec 21, 2025
pulisher
Dec 20, 2025

What hedge fund activity signals for Neurocrine Biosciences Inc. stock2025 Valuation Update & Weekly Sector Rotation Insights - Bölüm Sonu Canavarı

Dec 20, 2025
pulisher
Dec 20, 2025

How Neurocrine Biosciences Inc. stock valuations compare to rivals2025 Volatility Report & Fast Gaining Stock Reports - Улправда

Dec 20, 2025
pulisher
Dec 19, 2025

Merger Talk: Can Neurocrine Biosciences Inc. stock beat analyst upgrades2025 EndofYear Setup & Risk Managed Investment Entry Signals - moha.gov.vn

Dec 19, 2025
pulisher
Dec 19, 2025

Is Neurocrine Biosciences (NBIX) Quietly Recasting Its Long-Term Story Around Metabolic Disease Innovation? - simplywall.st

Dec 19, 2025
pulisher
Dec 19, 2025

How Neurocrine Biosciences Inc. (NB3) stock reacts to monetary easing2025 Earnings Surprises & Low Risk Entry Point Tips - ulpravda.ru

Dec 19, 2025
pulisher
Dec 19, 2025

How Neurocrine Biosciences Inc. stock performs in weak economyQuarterly Earnings Summary & Weekly Hot Stock Watchlists - Улправда

Dec 19, 2025
pulisher
Dec 19, 2025

Nxera Knocked Back As Boehringer Bows Out Of Schizophrenia Pact - Citeline News & Insights

Dec 19, 2025
pulisher
Dec 19, 2025

Is Neurocrine Biosciences Inc. (NB3) stock a momentum leaderPortfolio Gains Summary & Technical Pattern Recognition Alerts - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

Why Neurocrine Biosciences Inc. stock is favored by pension fundsQuarterly Market Summary & Growth Focused Entry Point Reports - DonanımHaber

Dec 19, 2025
pulisher
Dec 18, 2025

Neurocrine Bio. stock price target raised to $198 by H.C. Wainwright - Investing.com Canada

Dec 18, 2025
pulisher
Dec 18, 2025

Published on: 2025-12-18 16:31:37 - Улправда

Dec 18, 2025
pulisher
Dec 18, 2025

RBC Capital Keeps Their Buy Rating on Neurocrine (NBIX) - The Globe and Mail

Dec 18, 2025
pulisher
Dec 17, 2025

HC Wainwright & Co. Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq

Dec 17, 2025
pulisher
Dec 17, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 1,190 Shares - MarketBeat

Dec 17, 2025
pulisher
Dec 17, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 5,000 Shares - MarketBeat

Dec 17, 2025
pulisher
Dec 17, 2025

Neurocrine Biosciences Director Sells Shares - TradingView — Track All Markets

Dec 17, 2025
pulisher
Dec 17, 2025

Neurocrine Bio. stock price target reiterated at $200 by TD Cowen - Investing.com Canada

Dec 17, 2025
pulisher
Dec 17, 2025

Key facts: HC Wainwright maintains 'Buy' on Neurocrine; price target rises - TradingView — Track All Markets

Dec 17, 2025
pulisher
Dec 17, 2025

Neurocrine Bio. stock holds Buy rating at Jefferies after R&D Day - Investing.com Canada

Dec 17, 2025
pulisher
Dec 17, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Dec 17, 2025
pulisher
Dec 17, 2025

Neurocrine Bio. stock rating reiterated at Outperform by RBC Capital - Investing.com Canada

Dec 17, 2025
pulisher
Dec 17, 2025

Texas Permanent School Fund Corp Sells 11,976 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 17, 2025
pulisher
Dec 17, 2025

Neurocrine showcases R&D across neuroscience and endocrinology - The Pharma Letter

Dec 17, 2025
pulisher
Dec 17, 2025

Neurocrine Bio. stock holds steady as BMO reiterates $147 price target - Investing.com UK

Dec 17, 2025
pulisher
Dec 16, 2025

Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology - PR Newswire

Dec 16, 2025
pulisher
Dec 15, 2025

What analysts say about Neurocrine Biosciences Inc stockMomentum Trading Signals & Free Daily Top Stock Picks for All Investors - earlytimes.in

Dec 15, 2025
pulisher
Dec 15, 2025

Dir Norwalk Files To Sell 11,250 Of Neurocrine Biosciences Inc [NBIX] - TradingView — Track All Markets

Dec 15, 2025
pulisher
Dec 15, 2025

Hudson Bay Capital Management LP Has $9.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 15, 2025
pulisher
Dec 14, 2025

Neurocrine Biosciences (NBIX): Revisiting Valuation After a Year of Double-Digit Shareholder Returns - simplywall.st

Dec 14, 2025
pulisher
Dec 14, 2025

Thrivent Financial for Lutherans Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 14, 2025
pulisher
Dec 13, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat

Dec 13, 2025

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$12.32
price up icon 0.65%
drug_manufacturers_specialty_generic RDY
$14.16
price up icon 0.50%
$22.60
price up icon 0.98%
drug_manufacturers_specialty_generic RGC
$21.16
price down icon 13.98%
$507.16
price down icon 1.45%
大文字化:     |  ボリューム (24 時間):